Drug Profile
MK 1697
Alternative Names: MK-1697Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hong Kong (IV, Infusion)
- 10 Mar 2020 Merck Sharp & Dohme terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia and Hong Kong due to business reason (IV) (NCT03515824